Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Long-Term Investments (2016 - 2019)

VYNE Therapeutics (VYNE) has disclosed Long-Term Investments for 4 consecutive years, with $2.0 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Long-Term Investments changed N/A year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2019, changed N/A, and an annual FY2017 reading of $3.0 million, down 71.42% over the prior year.
  • Long-Term Investments was $2.0 million for Q3 2019 at VYNE Therapeutics, down from $10.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $20.7 million in Q1 2018 and bottomed at $2.0 million in Q3 2019.
  • Average Long-Term Investments over 4 years is $9.3 million, with a median of $10.4 million recorded in 2016.
  • Peak annual rise in Long-Term Investments hit 71.42% in 2017, while the deepest fall reached 71.42% in 2017.
  • Year by year, Long-Term Investments stood at $10.4 million in 2016, then tumbled by 71.42% to $3.0 million in 2017, then soared by 250.07% to $10.4 million in 2018, then plummeted by 80.78% to $2.0 million in 2019.
  • Business Quant data shows Long-Term Investments for VYNE at $2.0 million in Q3 2019, $10.4 million in Q2 2018, and $20.7 million in Q1 2018.